SLC9C1: A Potential Drug Target for Cellular Processes and Diseases

Target Name: SLC9C1

NCBI ID: G285335

SLC9C1

SLC9C1: A Potential Drug Target for Cellular Processes and Diseases

SLC9C1, also known as Na+-transporting carboxylic acid decarboxylase member 1, is a protein that belongs to the SLC9 family of proteins. This protein is primarily localized to the endoplasmic reticulum (ER) and play a crucial role in the transport of sodium ions (Na+) into the cytosol of the cell.

SLC9C1 is a transmembrane protein that consists of 482 amino acids. It has a calculated molecular mass of 61.1 kDa and a pre-calculated pI of 9.0. SLC9C1 is a monomer and its structure is defined by a single transmembrane region that contains a N-terminal cytoplasmic domain and a C-terminal transmembrane domain.

The N-terminal cytoplasmic domain of SLC9C1 contains a putative carboxylic acid site that is involved in the transport of sodium ions into the cytosol of the cell. This domain is also known as the \"Na+-transporting carboxylic acid decarboxylase\" domain and is responsible for the structural stability of the protein.

The C-terminal transmembrane domain of SLC9C1 is characterized by a series of conserved amino acid residues that are involved in the formation of a transmembrane region. This region is known as the \"endoplasmic reticulum-localized\" region and is responsible for the localization of the protein to the ER.

SLC9C1 is a member of the SLC9 gene family, which is characterized by a single gene that encodes a protein that is involved in the transport of various ions and molecules across the endoplasmic reticulum. The SLC9 gene family is characterized by the use of a variable region that is involved in the transport of different ions and molecules.

SLC9C1 has been identified as a potential drug target and a biomarker for various diseases, including heart failure, hypertension, and diabetes. The protein has been shown to be involved in the regulation of sodium ion transport and has been shown to play a role in the pathogenesis of these diseases.

SLC9C1 has also been shown to be involved in the regulation of other processes in the cell, including cell signaling, DNA replication, and protein synthesis. The protein has been shown to interact with a variety of molecules, including transcription factors, signaling proteins, and intracellular reactive oxygen species (ROS).

SLC9C1 has also been shown to play a role in the regulation of cellular processes that are important for the development and maintenance of the nervous system. The protein has been shown to be involved in the regulation of neurotransmitter release from neurons and in the development of neurodegenerative diseases.

In conclusion, SLC9C1 is a transmembrane protein that is characterized by its ability to transport sodium ions into the cytosol of the cell. The protein has a crucial role in the regulation of cellular processes and has been shown to be involved in the development and maintenance of various diseases. As a potential drug target and biomarker, SLC9C1 is a promising target for the development of new therapies for a variety of diseases.

Protein Name: Solute Carrier Family 9 Member C1

Functions: Sperm-specific sodium/hydrogen exchanger involved in intracellular pH regulation of spermatozoa. Required for sperm motility and fertility. Involved in sperm cell hyperactivation, a step needed for sperm motility which is essential late in the preparation of sperm for fertilization. Required for the expression and bicarbonate regulation of the soluble adenylyl cyclase (sAC) (By similarity)

The "SLC9C1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC9C1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets